drugset / Trial / NCT07234162
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase 3, open-label, randomized, multinational study to evaluate the anti-tumor efficacy of golidocitinib versus investigator's choice in adult patients with relapsed/refractory peripheral T-cell lymphoma (r/r PTCL). This study will treat patients with pathologically confirmed PTCL who have relapsed after or been refractory/intolerant to at least one prior systemic treatment regimen(s).
Timeline
- Start
- 2024-05-13
- Primary completion
- 2027-11-30
- Completion
- 2028-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Golidocitinib | Small molecule | 150 mg | Oral |
| Comparator | Tucidinostat | Small molecule | 30 mg | Oral |